Chennai-based startup LogicFlo AI, an artificial intelligence (AI) platform designed specifically for the life sciences sector, has raised $2.7 million in a seed round led by Lightspeed, with participation from leading healthcare and enterprise AI investors.
The funding will support LogicFlo AI’s global expansion across pharmaceutical, biotech, and medtech organisations, and enable deeper deployment with global clients, including a Fortune 500 company already under contract.
Founded by Udith Vaidyanathan and Arun Ramakrishnan (as seen in the image), the company is redefining how regulated scientific work is done by replacing fragmented tools and repetitive processes with intelligent AI agents that work under human guidance. Across regulatory affairs, medical writing, quality assurance, and medical information teams, LogicFlo AI enables experts to complete high-compliance workflows in a fraction of the time, without sacrificing accuracy or oversight.
The platform is already in production across several global life sciences companies, with early deployments showing transformative results: medical writing timelines reduced from weeks to minutes, and medical information response times cut from nearly two weeks to just two days. With growing demand and expanding agent libraries, LogicFlo AI is emerging as a foundational layer for regulated enterprises, redefining how complex scientific knowledge work is executed at scale.
With the new funding, LogicFlo AI will accelerate product development, expand integrations with life sciences systems like Veeva and IQVIA, and grow its go-to-market and technical teams to meet rising industry demand. The company's broader vision is to redefine how scientific work happens, empowering every expert with tools that match the speed and complexity of modern science.
